Description du projet
De minuscules dispositifs libèrent les médicaments précisément au bon endroit
Ne vous laissez pas tromper par leur petite taille! De minuscules dispositifs magnétiques mobiles revêtent un immense potentiel pour de futures applications biomédicales. Toutefois, l’utilisation de ces micro- et nanodispositifs dans des environnements cliniques n’est pas simple. Le projet ANGIE, financé par l’UE, ira de l’avant avec la robotique à petite échelle, les systèmes de navigation magnétique et l’administration ciblée et localisée de médicaments. Plus précisément, le projet développera des nanodispositifs sans fil magnétiquement dirigeables pour l’administration ciblée d’agents thérapeutiques via le système vasculaire du corps. En créant une base de connaissances et de compétences pour l’administration ciblée et localisée de médicaments, le projet améliorera la capacité des professionnels de la santé à traiter différentes maladies chroniques. En outre, il permettra aux médecins d’administrer les médicaments précisément où ils sont attendus avec un minimum d’effets secondaires.
Objectif
The past decade has seen exciting progress in the field of mobile magnetic small-scale devices. These tiny machines have demonstrated great potential for biomedical applications. However, current mobile micro- and nanodevices do not meet the conditions for their translation into medical practice. The use of these devices in clinical settings implies specific requirements and constraints that are often conflicting and imply substantial challenges that are not considered in lab-scale research. The ANGIE project puts forward a radically new technology that is far beyond the current state of the art in the field of micro/nanorobots, and implies major progress in small-scale robotics, magnetic navigation systems, and localized targeted drug delivery. ANGIE will create a solid baseline of knowledge and skills for localised targeted drug delivery based on steerable wireless nanodevices, capable of navigating the body vascular system to deliver drugs where no other instrument can go. ANGIE will offer health professionals vastly improved intervention capacity to tackle multiple chronic diseases and enable them to deliver drugs precisely where needed, with minimal side effects. To assemble the interdisciplinary communities around this technology and to demonstrate its potential to mitigate the impact of chronic health conditions, we will apply the ANGIE technology for the localized treatment of thrombotic stroke. ANGIE is supported by stakeholders representing a broad spectrum of European organizations and citizens, such as large multinationals (e.g. Siemens and CLS Behring), policy makers (e.g. health systems and healthcare facilities), as well as civil society organizations (e.g. associations of health professionals and stroke patients). These stakeholders will help us create an innovation eco-system around our radically new technology and will play vital advisory roles regarding the feasibility, transferability, and exploitability of the proposed technology.
Champ scientifique
- medical and health sciencesbasic medicineneurologystroke
- social sciencespolitical sciencespolitical policiescivil society
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringrobotics
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technology
- social sciencessocial geographytransportnavigation systems
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
8092 Zuerich
Suisse